Funding for this research was provided by:
National Institute on Aging (U01AG061357, U01AG046161, R01AG057339, RF1AG057471, RF1AG062181, RF1AG057470, P50AG025688, R01AG053960, R01AG061800)
Received: 5 February 2020
Accepted: 19 May 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: All participants from whom CSF samples were collected provided informed consent under protocols approved by the institutional review board (IRB). Symptomatic individuals with mild cognitive impairment (MCI) or mild AD, received clinical evaluations in the Emory Cognitive Neurology clinic with the CSF collection for clinical reasons. All cognitively impaired individuals were accompanied by spouse or other family member and met additional IRB safeguards for protection of vulnerable populations. Cognitively intact control individuals were recruited through the Goizueta Alzheimer’s Disease Research Center (ADRC) at Emory or the Emory Healthy Brain Study under IRB approved protocols.
: All Authors consent to publication.
: The authors declare no competing financial interest.